MAFENIDE ACETATE

Post-LOE

mafenide acetate

Pfizer

ANDATOPICALFOR SOLUTION

Approved

Feb 2013

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

MAFENIDE ACETATE (mafenide acetate) by Pfizer is clinical pharmacology sulfamylon cream, applied topically produces a marked reduction in the bacterial population present in the avascular tissues of second- and third-degree burns. First approved in 2013.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY SULFAMYLON Cream, applied topically produces a marked reduction in the bacterial population present in the avascular tissues of second- and third-degree burns. Reduction in bacterial growth after application of SULFAMYLON Cream has also been reported to permit spontaneous…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on MAFENIDE ACETATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.